New shot aims to stop deadly fever outbreak
NCT ID NCT06799234
Summary
This study is testing a new vaccine designed to protect people from Rift Valley Fever, a serious mosquito-borne disease that can cause severe bleeding and death. Researchers are giving the vaccine to 240 healthy adults in Kenya to see if it safely triggers a strong and lasting immune response. They are comparing one dose versus two doses of the vaccine against a standard rabies vaccine to find the best approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIFT VALLEY FEVER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
KEMRI-Wellcome Trust Research Programme
Kilifi, Coast, 254, Kenya
Conditions
Explore the condition pages connected to this study.